Upstate Active Clinical Trials

Study Title:

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR’S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC REAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR BASED THERAPY.

What is the purpose of the study? (in Layman's terms, please describe the study)

The purpose of this study is to compare the effects of the investigational drug PF 07220060 in combination with fulvestrant with comparison drugs that are approved in many countries for the treatment of your type of breast cancer .

Upstate Institutional Review Board (IRB) Number:

2128296

Study/Protocol ID:

C4391022

Study Phase:

phase 3

Patient Age Group:

Adults

Principal Investigator:

Sam Benjamin, MD

Who is eligible?

patients with locally advanced or metastatic breast cancer.

What is involved if I participate?

• How long is the study?
  upto 5years
• Is transportation provided or reimbursed?
  Yes
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  CT scans, MRIs or whole-body bone scans

Where will the study take place?

SUNY Upstate Cancer Center

Other Information:

N/A

Who can I contact for more information?

Name: Manjusha Kondepudi
Phone: 315-464-3732
Email: [email protected]

Return to Previous Page || Search Again